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Viral reservoirs of HIV-1 are a major obstacle for curing AIDS. The novel animal models that can be
directly infected with HIV-1 will contribute to develop effective strategies for eradicating infections.
Here, we inoculated 4 northern pig-tailed macaques (NPM) with the HIV-1 strain HIV-1NL4.3 and moni-
tored the infection for approximately 3 years (150 weeks). The HIV-1-infected NPMs showed transient
viremia for about 10 weeks after infection. However, cell-associated proviral DNA and viral RNA persisted
in the peripheral blood and lymphoid organs for about 3 years. Moreover, replication-competent HIV-1
could be successfully recovered from peripheral blood mononuclear cells (PBMCs) during long-term
infection. The numbers of resting CD4+ T cells in HIV-1 infected NPMs harboring proviruses fell within
a range of 2- to 3-log10 per million cells, and these proviruses could be reactivated both ex vivo and
in vivo in response to co-stimulation with the latency-reversing agents JQ1 and prostratin. Our results
suggested that NPMs can be infected with HIV-1 and a long-term viral reservoir was formed in NPMs,
which might serve as a potential model for HIV-1 reservoir research.1. Introduction
In contrast to two other widely used macaque species, rhesus
macaques and cynomolgus macaques, pig-tailed macaques (PTM)
are the only type of macaque that can be infected with HIV-1
[1–9]. Our group and others identified a unique TRIM5-
cyclophilin fusion gene isoform in PTM that replaces TRIM5a and
lacks the ability to restrict HIV-1 infection [10–12]. This finding
provided an explanation on why PTM are susceptible to HIV-1 infec-
tion and experience AIDS-like symptoms in response to infection
with engineered simian-tropic strains of HIV-1 (stHIV-1) [13–16].
On the other hand, although some researches in early reports
have a suspicion that HIV-1 might be hidden at some site remoteg).from peripheral circulation, with a very low-level replication
because of persistent detectable antibodies and provirus genes
[5,8], few researches were carried out to evaluate the features of
the hidden viruses in HIV-1 infected pig-tailed macaques, which
is equally significant so as to reveal the other side of HIV-1 infec-
tion. Additionally, pig-tailed macaques (Macaca nemestrina group)
are now divided into 3 species: Sunda pig-tailed macaque (M.
nemestrina), northern pig-tailed macaque (M. leonina, NPM) and
Mentawai macaque (M. pagensis) according to the current
widely-accepted primate taxonomy [17,18]. The previously stud-
ied pig-tailed macaques were mainly Sunda pig-tailed macaques
that originate in Sumatra and, to a lesser extent, Borneo [19]. In
China the local pig-tailed macaque species is NPM, which has a dif-
ferent distribution range and morphological characteristics that
are distinct from M. nemestrina [20]. We previously found that
peripheral blood mononuclear cells (PBMCs) from NPMs lacking
the TRIM5a gene [21] are amenable to HIV-1 replication in vitro,
too [22].
In this study, we inoculated 4 NPMs with the HIV-1 strain HIV-
1NL4.3 and monitored the infection for about 3 years. The results
showed that HIV-1 successfully established an infection in all 4
animals to produce a peak plasma viral load in the early stages
of infection and persistent HIV-1 antibodies during the observation
period. Although the initial viremia declined to undetectable levels
during the post-acute infection stages, proviral genes and viral
RNA, as well as HIV-1 particles, could be detected throughout the
infection period. More importantly, upon treatment with a combi-
nation of the LRAs, JQ1 and prostratin, proviruses harbored in rest-
ing CD4+ T cells of these animals could be reactivated ex vivo and
in vivo even at 3 years after infection. These results suggested that
HIV-1 can infect NPMs and form viral reservoirs in vivo.2. Materials and methods
2.1. Animals and infection
The four northern pig-tailed macaques (Macaca leonina, NPM)
used in this study were provided by Guangdong Landao Biotechnol-
ogy, Co., Ltd., China. All applicable institutional and/or national
guidelines for the care and use of animals were followed. The NPMs
used were two adult males: 05001, 05003 and two adult females:
04002, 05004, aged 6- to 7 years old. The males and females
weighed 7- to 8 kg and 4- to 5 kg, respectively. Nested-PCR analyses
at the start of the study showed that all animals were free from
simian immunodeficiency virus (SIV), simian type-D retrovirus,
and simian T-lymphotropic virus type 1. Ethylenediaminetetraacetic
acid (EDTA)-blood (5–10mL) was collected from the animals at each
time point and centrifuged to separate the plasma from the cellular
fraction. Peripheral blood mononuclear cells (PBMCs) were isolated
by Ficoll (GE Healthcare) gradient centrifugation. Plasma and PBMCs
were frozen in aliquots at 80 C before use.
HIV-1NL4.3 virus stocks were generated from the supernatant of
293T cells transfected with pNL4.3 proviral plasmid, and expanded
by brief passage in C8166 cells. PBMCs (1  107) from each animal
were infected with HIV-1NL4.3 particles at a multiplicity of infection
(MOI) of 0.01. Three days later, autologous PBMCs (1  107) and
1 mL of cell free virus stocks containing 2 ng HIV-1 p24 antigen
were intravenously (IV) inoculated into each animal.2.2. Plasma viral load measurements
The levels of viral RNA in plasma were quantified by a real-time
PCR method based on amplification of a HIV-1NL4.3-derived Gag
coding sequence described previously with slight modification
[23]. Briefly, total RNA eluted in a 50-mL volume was extracted
from 200-mL plasma using the High Pure Viral RNA Kit (Roche, Indi-
anapolis, Indiana, USA). For each sample, three separate 10-mL ali-
quots of eluted RNA were reverse-transcribed with SuperScript II
reverse transcriptase (Invitrogen Carlsbad, California, USA) and
the gene special reverse primer 84R (50-TGCTTGATGTCCCCC
CACT-30). Each total cDNA template was subjected to real time
PCR amplification in a 50-mL volume with 1  PCR II buffer,
1  ROX reference, 4 mM MgCl2, 0.6 lmol/L primers, 0.1 lmol/L
probe, 0.3 mmol/L dNTP, and 1.25 units AmpliTaq Gold DNA poly-
merase (Applied Biosystems). The primers were 6F (50-CATGTTTT
CAGCATTATCAGAAGGA-30) and 84R (50-TGCTTGATGTCCCCCCACT-
30), and the probe 50-FAM-CCACCCCACAAGA-TTTAAACACCATGC
TAA-TAMRA-30. PCR reactions were performed on an ABI Vii7
Sequence Detection System under the conditions of 1 cycle of
95 C for 10 min followed by 45 cycles of 95 C for 15 s and 60 C
for 1 min. The quantitation limit was determined to be 50 copies/
mL by a standard curve constructed from serial dilutions of an
appropriate RNA transcript.2.3. Flow cytometry
Antibodies and reagents were obtained from BD Biosciences
(BD, Franklin Lakes, NJ, USA). Surface staining for lymphocyte
immunophenotyping was performed as previously described.
Briefly, 100 mL of whole blood was lysed with FACS Lysing
Buffer for 10 min at room temperature. After washing with DPBS
containing 2% newborn calf serum and 0.09% sodium azide
(staining buffer), the residual leukocytes were resuspended in
staining buffer followed by staining with the relevant mAbs for
30 min on ice, and then fixed in PBS containing 4%
paraformaldehyde. For Ki67 staining, 1  105 leukocytes were
first stained with relevant surface marker mAbs, fixed and per-
meabilized in Cytofix/Cytoperm solution, washed in Perm/Wash
Buffer, and incubated with anti-Ki67 PE mAb in Perm/Wash Buf-
fer. After washing once, the cells were fixed with PBS containing
2% paraformaldehyde and then resuspended in a staining buffer.
Flow cytometric data acquisition was performed on a BD FACS-
Verse cytometer driven by FACSuite software (version 1.0.3;
BD). FlowJo software (version 7.6.1; TreeStar) was used for data
analysis.
The surface marker mAbs used were: anti-CD3-PE/-APC-Cy7
(clone SP34-2), anti-CD4-FITC/-PerCP-Cy5.5 (clone L200),
anti-CD8a-PE-Cy7 (clone RPA-T8), anti-CD20-PerCP-Cy5.5 (clone
2H7), anti-CD14-APC (clone M5E2), anti-HLA-DR-APC
(clone L243), anti-CD28-APC (clone CD28.2), anti-CD95-FITC (clone
DX2), anti-Ki67-PE (clone B56), Anti-CD38-FITC (clone AT-1), anti-
CD21 APC (clone B-ly4) and anti-CD25 (BC96).2.4. Anti-HIV-1 antibody
HIV-1-specific antibodies were measured by ELISA using the
Anti-HIV antibody ELISA kit (WANTAI Bio-pharm, Beijing, China).
Briefly, plasma at the relevant time points was serially diluted
and distributed into 96-well plates and the anti-HIV IgG antibody
titers were determined according to the manufacturer’s protocol.2.5. Cell-associated HIV-1 RNA and DNA
PBMCs (4  106) or resting CD4+ T cells (4  105) were split
into two equal parts to measure cell-associated HIV-1 DNA and
RNA. Total cellular DNA was extracted using the QIAmp DNA Blood
Mini Kit (Qiagen, German) and eluted in a 100 mL volume. HIV-1
DNA was quantified by qPCR using the same primers and probes
for HIV-1 RNA quantification mentioned above, and a pNL4.3 plas-
mid with known copies as quantified by spectrophotometric anal-
ysis was prepared to generate a standard curve. Meanwhile, cell
numbers were assessed in parallel by genomic CCR5 DNA that
was quantified with primers 50-AGCCAGGACGGTCACCTT-30 (for-
ward) and 50-ATGATTCCTGGGAGAGACGC-30 (reverse) and the
sequence-specific probe 50-FAM-AACACAGCCACCACCCAAGT
GATCA-30-TAMRA. Each reaction contained 10-mL total DNA in a
25-mL reaction volume. Reaction mixtures and conditions were as
mentioned above and the quantitative limit was proposed to be
5 copies per reaction. HIV-1 DNA levels were normalized as copy
numbers relative to CCR5 genomic DNA copies per equivalent
sample.
Cell-associated RNA was extracted by Trizol (Invitrogen)
reagent and dissolved in 100-mL volume. A 10-mL aliquot was quan-
tified for HIV RNA by the same procedures as described above for
plasma viral RNA. The lower limit of detection was determined
to be 5 copies of viral RNA per qRT-PCR reaction. Cell-associated
HIV-1 RNA is presented as the number of HIV-1 RNA copies per
sample relative to CCR5 genomic DNA copies per equivalent sam-
ple measured above.
2.6. Virus isolation and sequence analysis
For virus isolation, PBMCs isolated from the inoculated animals
at given time points were depleted of CD8+ cells (CD8-depleted
PBMCs) using CD8 MicroBeads (Miltenyi). CD8-depleted PBMCs
(2  106) were cultured in 2 mL medium containing 10 mg/mL
Con A. Meanwhile, HIV-1 sero-negative human PBMCs were
depleted of CD8+ cells using the same methods and stimulated
with 5 mg/mL PHA-P. Three days later, the medium was completely
replaced and 1  106 human CD8-depleted PBMCs were added. All
cultures were maintained in RPMI-1640 with 10% FBS, 100 U/mL
penicillin, 100 mg/mL streptomycin, and 50 U/mL IL-2. Co-cultures
were split 1:2 every 3 to 4 days and new stimulated human CD8-
depleted PBMCs were added every 7 days. HIV-1 expression was
monitored after 21 days by HIV-1 p24 antigen ELISA (ZeptoMetrix,
Buffalo, NY, USA).
HIV-1 gag and env sequences were amplified by nested PCR
from PBMC DNA isolated using the QIAmp DNA Blood Mini Kit
(Qiagen). Nested PCR was performed with previously described
primers, DNA polymerase, and conditions [15]. Single-genome
sequencing of HIV-1 env was performed as previously described
[24]. Briefly, cellular DNA was serially diluted and distributed in
the wells of 96-well plates. The aforementioned nested PCR proce-
dure for the env gene was carried out in each well. A dilution where
the positive ratio was <30% was used for at least 8 more positive
amplifications. The amplicon can be considered to be derived from
a single DNA molecule. Phylogenetic trees using the resulting DNA
sequences were generated by MEGA5 and hypermutation analysis
using Hypermut 2.0 (http://www.hiv.lanl.gov/content/sequence-/
HYPERMUT/hypermut. html).
2.7. Viral reservoir reactivated ex vivo and in vivo
Two latency reversing agents were used: prostratin (Santa Cruz,
Dallas, Texas, USA), JQ1 (Selleck, USA). PHA-P (Sigma-Aldrich, USA),
and Con A (Sigma) were used as positive controls. PBMCs or resting
CD4+ T cells isolated from the inoculated animals at various time
points were isolated as mentioned above. PBMCs (1  106)
were treated with the indicated agents (JQ1, 250 nmol/L; PHA,
5 mg/mL; ConA 10 mg/mL or prostratin, 250 nmol/L) alone or with
JQ1 and prostratin combined for 48 h; DMSO was used as a nega-
tive control. The cells were collected and cellular RNA was
extracted with Trizol (Invitrogen). Cell-associated HIV-1 RNA or
DNA levels were determined as mentioned above.
For viral reservoir in vivo, JQ1 and prostratin were diluted in 5-
mL normal saline and used to intravenously (IV) inject the NPMs
with a combined dose of 100 mg/kg and 80 mg/kg, respectively.
Three weeks later, the compounds were again inoculated into the
animals at the same dosages. One of the animals, 05001, received
a third dose at 9 weeks after the second dose. This animal was sac-
rificed 48 h after LRA treatment and the PBMCs, ileum, colon, ingu-
inal lymph nodes (ILN), mesenteric lymph nodes (MLN), and spleen
were isolated at necropsy.
2.8. Isolation of resting CD4+ T cells
Gut lymph nodes (mesenteric and colonic), peripheral lymph
nodes (axillary and inguinal) and spleen tissue were minced and
pressed through nylon mesh screens to obtain single-cell suspen-
sions of lymphocytes. PBMCs were separated from whole blood.
Lamina propria mononuclear cells (LPMCs) from ileum (LPMCile)
and colon (LPMCcol) tissues were isolated as described [25]. In
brief, intestinal tissues were cut into 1 cm pieces and digested with
collagenase and DNase. The LPMCs were pressed through nylon
mesh screens and purified with Ficoll gradient centrifugation to
obtain >85% purity as tested by flow cytometry analysis.Cell populations were then enriched for resting CD4+ T cells by
magnetic bead separation. Briefly, biotin-conjugated monoclonal
antibodies against HLA-DR (LN3, BioLegend, San Diego, CA, USA)
and CD25 (BC96, eBioscience, San Diego, CA, USA) were added into
a biotin-antibody cocktail from the CD4+ T Cell Isolation Kit (non-
human primate, Miltenyi Biotec, Inc. Auburn CA, USA) to deplete
cells expressing CD25, HLA-DR, CD8, CD11b, CD16, CD20, CD56,
and CD66abce, and leaving a population of HLA-DR-CD25- CD4+
T cells. FACS analysis showed that resting CD4+ T cells were present
at >95% purity.
2.9. Immunohistochemistry
Tissues were paraformaldehyde-fixed, paraffin-embedded, and
consecutively cut into 5 lm sections that were mounted on glass
slides for hematoxylin and eosin (HE) staining and immunohisto-
chemistry analysis. Antigen retrieval was performed by heating
sections at 100 C for 6 min three times in saline sodium citrate buf-
fer (SSC), followed by cooling to room temperature (RT) and wash-
ing with phosphate-buffered saline containing 0.05% Tween-20
(PBST). The sections were then incubated with 0.1% TritonX-100
for 10 min at RT, washed, treated with 3% hydrogen peroxide for
10 min at RT, washed, and then blocked with 10% bovine serum
albumin (BSA) at 37 C for 60 min. The primary antibody anti-
HIV-1 p24 mAb P6F1 generated by our laboratory [26] or mouse
anti-LPS core (WNA 22-5; Hycult Biotech, PA, USA) were diluted
in BSA and incubatedwith the sections overnight at 4 C. Thereafter,
the sections were washed and secondary antibodies conjugated
with horseradish peroxidase (HRP) were added. After incubation
in BSA for 60 min at RT, 30-diaminobenzidine tetrahydrochloride
(DAB) was used as a substrate to yield a deep brown color, and
counterstained with hematoxylin. Sections were mounted on a
Leica DMI 4000B (Leica Microsystems, Wetzlar, Germany).
2.10. Statistics
Significance between paired data of 4 macaques was deter-
mined by paired t test. Difference between LRA-treatment groups
was calculated by one-way analysis of variance. Correlations were
determined by the Spearman rank method. For all tests, a P value
less than 0.05 was considered statistically significant.
2.11. Study approval
Macaques were housed in the ABSL-3 laboratory at the Kunming
Primate Research Center, Kunming Institute of Zoology, Chinese
Academy of Sciences in accordance with the regulations of the
American Association for Assessment and Accreditation of Labora-
tory Animal Care (AAALAC). All experimental procedures were per-
formed according to the guidelines approved by the Ethics
Committee of the Kunming Institute of Zoology (approval ID:
SYDW-2011009). Efforts were made to minimize suffering of the
macaques. For invasive procedures such as intravenous injections
and blood collection, macaques were anesthetized by intramuscu-
lar injection 2 mg/kg of xylazine hydrochloride. For euthanasia,
macaque 05001 was injected intravenously 80 mg/kg of pelltobar-
bitalum natricum combined intramuscularly 10 mg/kg of ketamine
hydrochloride.
3. Results
3.1. Establishment of HIV-1NL4.3 infection in northern pig-tailed
macaques (NPM)
We have shown that HIV-1 could replicate in PBMCs of NPMs
[22]. Here, 4 juvenile NPMs, two males and two females, were
inoculated intravenously with HIV-1NL4.3. Infection was success-
fully established in all 4 animals, and a peak plasma viral load of
104 to 105 copies of viral gag RNA (vRNA) per mL was reached at
1 week after inoculation. Thereafter, the viremia decreased gradu-
ally, and by 6 weeks post-infection (wpi), there were fewer than 50
copies/mL (the detectable limit) of vRNAs in all 4 macaques. Spo-
radic blips of plasma vRNAs were detected between 6 and 12
wpi, thereafter, vRNAs cannot be detected in plasma during the
observed times (Fig. 1a). A mild but temporary decline in the num-
ber of CD4+ T cells in peripheral blood was observed during pri-
mary HIV-1 infection (5 to 14 wpi) but after this period the
numbers recovered. However, these decline of CD4+ T cell numbers
can hardly be attributed to HIV-1 replication, for the lack of other
haematological data and contemporaneous analyses of co-housed
uninfected macaques (Fig. 1a, b).
To confirm HIV-1 infection, antibodies against whole HIV-1
antigens were measured by ELISA. All infected animals developed
HIV-1 antibodies that were detectable at 4 wpi. Antibody titers
peaked at 8 wpi and then remained at high levels. However, the
patterns of antibody responses differed among the 4 animals. For
example, animal 05001 generated robust antibody titers and peak
values over 3000, which was consistent with the high B cell levels
seen in this animal (Fig. S1). Meanwhile, the other three animals
mounted 10- to 100-fold lower antibody responses relative to ani-
mal 05001 during the course of the infection (Fig. 1c).
We also evaluated immunological changes in NPM after HIV-1
infection by analyzing the numbers of CD8+ T and B cells in periph-
eral blood (Supplementary Fig.1a, b), the subpopulation of CD4+ T
cells (Fig. S1c), the abilities of CD4+ and CD8+ T cells to express
Th1 cytokines (IFN-c, IL-2 and TNF) and Th2 cytokines (IL-4 and
IL-13) (Fig. S1d-g), and the activation status of the CD4+, CD8+ T cell
and B cells (Fig. S2). All of these parameters showed few changes
during the course of infection. The animals experienced no fever,
weight loss, or diarrhea. Together these data implied that HIV-
1NL4.3 infection caused few immunological perturbations in NPM.
Thus, HIV-1 could infect NPM without high and persistent vire-
mia or pathogenicity. Yet the persistent antibodies to HIV-1
observed during the course of infection might support the possibil-
ity that the HIV infection persists in vivo for 3 years and that the
virus might be replicating at a low level.3.2. A stable viral reservoir was formed in HIV-1NL4.3 infected NPMs
Although viral RNA in plasma could not be detected in infected
NPM at 12 wpi, nested PCR assays showed the presence of the
proviral genes gag and env in PBMCs taken from 4 infected animals
at various time points during the infection. The exception was a
negative result for env in animal 04002 at 137 wpi (Table S1). Con-
sidering that the half-life of unintegrated, cytoplasmic provirus is
roughly 1 day [27,28], these results suggested that the viruses
were not eliminated, but were instead consistently integrated inFig. 1. (Color online) HIV-1NL4-3 infection of northern pig-tailed macaques (NPMs). Four N
approximately 3 years. (a) Plasma viral load measurements; (b) CD3+ CD4+ T-cell countthe host genome. Subsequently, detailed information concerning
provirus sequences provided by single viral genome amplification
and sequencing (SGA) revealed that a few, but not accumulated,
G? A mutations were present in the env sequences (Fig. S3).
These mutations might have been induced by host APOBEC3 pro-
teins [29,30]. Of note, there were some sequences that were iden-
tical to that of the inoculated virus, suggesting that the proviruses,
to a certain degree, consisted of original viral genomes that were
established upon primary infection. However, because of the lim-
ited numbers of the env sequences in each monkey (Fig. S3),
whether these proviruses resulted from low-level HIV-1 replica-
tion or had spread during the acute infection phase is difficult to
determine.
We then used quantitative PCR to further assess the numbers of
viral gag DNA and RNA in PBMCs from the infected animals. PBMC-
associated viral DNA was consistent with the PCR amplification
results, with a peak at 2 wpi and then maintenance of about 100
copies per million PBMCs (Fig. 2a). However, by 134 wpi the viral
RNA in PBMCs declined slowly but consistently from 10,000 copies
per million PBMCs to about 100 copies per million PBMCs (Fig. 2b).
Interestingly, in the presence of viremia, the plasma viral load sig-
nificantly correlated with PBMC-associated viral RNA (r = 0.78,
P = 0.001; Fig. 2d) but not DNA (r = 0.15, P = 0.39; Fig. 2c), suggest-
ing that a relatively stable viral reservoir was formed during the
initial infection, even though virus replication was impeded at this
stage. Meanwhile, during the whole process of infection, viral RNA
and DNA in PBMCs had a strong positive correlation (r = 0.25,
P = 0.035), suggesting that some proviruses were consistently acti-
vated (Fig. 2e).
In the absence of viremia, PBMC-associated HIV-1 RNA levels
represented the numbers of HIV-1 transcripts, which could provide
a useful alternative biomarker to plasma viral RNA in vivo [31]. The
apparent stabilization of HIV DNA and the persistence of HIV RNA
transcription in PBMCs implied that HIV-1 was viable and might
replicate at a low level in the 4 infected NPMs.
To address whether or not the putative proviruses could be
reactivated, we isolated CD8-depleted-PBMCs from infected ani-
mals and co-cultured these cells with CD8-depleted-PBMCs from
healthy human donors in the presence of Con A and IL-2. In con-
trast to previous reports in which HIV could not be recovered dur-
ing late infection stages in infected pig-tailed macaques [9], here
we showed that HIV-1 particles could be successfully amplified
even at 137 wpi in all 4 NPMs (Table S1, Fig. 2f). This result con-
firms that a persistent HIV-1 infection was established and
replication-competent viruses could be recovered after potent
stimulation of PBMCs with a Con A/IL-2 mitogen cocktail ex vivo.3.3. HIV viral reservoir can be induced ex vivo by JQ1 and prostratin
The relative homeostasis of HIV-1 DNA and the decline in HIV-1
RNA levels in PBMCs at longitudinal post-infection time pointsPMs were inoculated intravenously with HIV-1NL4-3 and monitored the infection for
s in peripheral blood; (c) HIV-1 special IgG antibody titers by ELISA.
Fig. 2. (Color online) HIV-1 transcription can be detected and HIV-1 particles can be recovered from four infected NPMs. Longitudinal analysis of PBMC-associated (a) DNA
and (b) RNA levels in HIV-1NL4.3 infected NPMs. (c) Correlation of plasma viral load with PBMC-associated DNA and (d) RNA. (e) Correlation of PBMC-associated RNA with
PBMC-associated DNA. P values were calculated by Spearman rank method. (f) Virus isolation by co-culturing CD8-depleted PBMCs from HIV-1-infected NPMs with human
PBMCs. HIV-1 replication in the supernatant was detected by p24 ELISA at 21 days post co-culture.suggested that the transcription of a significant number of pro-
viruses was gradually impeded, which raised the possibility that
in macaques a large proportion of viral DNA was maintained in a
dormant state during the course of infection. Therefore, to deter-
mine whether these viruses can be reactivated at late infection
time points, we isolated PBMCs from infected animals at 130 wpi
and stimulated them with the latency-reversing agents (LRAs)
JQ1 and prostratin. Compared with baseline levels, a single JQ1
(250 nmol/L) or prostratin (250 nmol/L) dose modestly increased
HIV-1 gag expression by about 5.0 and 5.8-fold, respectively. Given
that prostratin can boost HIV-1 transcription initiation byactivating NF-jB [32,33], and that JQ1 affects HIV-1 transcription
elongation by promoting the release of PTEF-b from BRD4
[34,35], the combination of these two LRAs could potently increase
latent gag RNA expression, as evidenced by the28- fold (21.5–39.7)
increase in expression in NPM PBMCs. This synergistic effect was
comparable to the increase in expression produced by PHA (25.0-
fold), and was slightly weaker than that of Con A (70.5-fold)
(Fig. 3a). Of note, the JQ1-prostratin combination did not induce
global T-cell activation in parallel co-cultures (Supplemental
Fig. 4). Together these results show that the combination of JQ1
and prostratin could robustly reactivate the latent viruses ex vivo.
Fig. 3. (Color online) HIV-1 reactivation by ex vivo stimulation. (a) PBMCs from the infected NPMs at 130 wpi and (b) Resting CD4+ T cells from the infected NPMs at 134 wpi
were treated with JQ1 and prostratin. After a 48 h co-culture, cell-associated HIV-1 RNA was quantified by RT-PCR. DMSO served as the negative control, and PHA and Con A
were the positive controls for both treatments. The differences between LRA-treatment groups were assessed by one-way analysis of variance. The activation levels of resting
CD4+ T cells were evaluated by surface staining of (c) CD25 and (d) HLA-DR in parallel. The P values between treatment and non-treatment groups of activation levels were
determined by paired t test.Considering that the resting CD4+ T cells harboring latent,
replication-competent HIV-1 DNA can act as a stable viral reservoir
and present a major obstacle to eradicating HIV-1 [36], we next
determined whether latent virus harbored in resting CD4+ T cells
can be reactivated by JQ1 and prostratin. We isolated resting
CD4+ T cells from PBMCs of each inoculated NPM at 134 wpi by
depleting other cells with antibody-coated magnetic beads (Fig. S5),
and evaluated the changes of HIV-1 gag expression after treatment
with the same concentration of JQ1 and prostratin used to stimu-
late PBMCs. We found that JQ1 and prostratin could robustly acti-
vate latent gag transcription in resting CD4+ T cells (Fig. 3b)
without altering CD25 and HLA-DR expression (Fig. 3c, d). An opti-
mum expression level of resting CD4+ T cell-associated HIV RNA (rc
RNA) emerged 48 h after JQ1 and prostratin exposure, and was
increased by about 16-fold relative to pre-treatment levels, which
was consistent with recent studies that showed stimulation of
latent virus in resting CD4+ T cells isolated from human patients
on long-term antiretroviral therapy [34,37]. Together, these results
demonstrated that HIV-1 was latent in infected NPM and was sim-
ilar to human patients in that latent infection could be potently
reactivated ex vivo from both PBMCs and resting CD4+ T cells. As
such, resting CD4+ T cells from NPM might serve as a potential pri-
mary cell model to assess LRAs and latency-reversing strategies.
3.4. Viral reservoir in peripheral blood can be reactivated by JQ1 and
prostratin in vivo
Because the combination of JQ1 and prostratin could potentially
induce HIV-1 gene transcription ex vivo, we evaluated the reactiva-tion of HIV-1 replication in vivo. At 138 wpi each macaque was
treated with both JQ1 (100 mg/kg) and prostratin (80 mg/kg) by
intravenous injection. As early as 6 h after administration, animals
04002 and 05004 showed a rapid rebound of virus replication. At
24 h post-injection, HIV-1 viral RNA could be detected in the
plasma of all the macaques at a mean of 119 copies/mL. The plasma
viral loads peaked at 48 h post-injection and varied significantly
among the test animals, ranging from 102 to 103 viral RNA
copies/mL. The viral RNA levels then decayed rapidly, and within
24 h of injection were near (animal 05001) or below (the other 3
animals) the limit of detection at 72 h post-injection, thus indicat-
ing that the effect of LRA co-stimulation was transient (Fig. 4a).
Additionally, an increase in the expression of HIV-1 gag RNA in
PBMCs was detected in these animals after exposure to JQ1 and
prostratin. Consistent with the reappearance of plasma virus,
PBMC-associated viral RNA increased 7-fold (range 4.4–11.0) 6 h
after administration and peaked at 59-fold (range 34.8–82.6)
48 h after administration relative to the baseline. Thereafter, the
levels decreased and within 72 h of treatment returned to pre-
treatment levels (Fig. 4b). However, PBMC-associated DNA levels
did not change significantly during JQ1 and prostratin treatment
(Fig. 4c). The level of cell-associated viral DNA represents the size
of proviral DNA genome, and can partly act as a surrogate indicator
of the HIV-1 reservoir. Thus, these observations indicated that
some proviruses could be reactivated from a relatively stable
HIV-1 reservoir in these infected NPM.
All macaques tolerated the LRA dose used and showed no obvi-
ous clinical side effects. Meanwhile, the main subpopulation and
activation status of immune cells in each animal fluctuated but
Fig. 4. (Color online) HIV-1 replication rebound after in vivo administration of JQ1 and prostratin. Infected NPMs were injected intravenously twice with JQ1 and prostratin at
138 and 141 wpi. The (a) plasma viral load, (b) PBMC-associated viral RNA, regular and (c) PBMC-associated viral DNA, regular were analyzed by real-time PCR. Dose 1 and 2
indicate the first and second administration of JQ1 and prostratin, respectively.returned to pre-treatment levels within 7d (Figs. S6 and S7). Thus,
a second injection of JQ1 and prostratin at the same dose was given
to each macaque 3 weeks after the first dose, at 141 wpi. The
changes in plasma HIV RNA, PBMC-associated viral RNA and DNA
were consistent with those produced by the first treatment
(Fig. 4), confirming that the viral reservoirs in infected macaques
could be reactivated in vivo.
3.5. Viral reservoir harbored in peripheral blood can be reactivated
in vivo
Because the levels of plasma and PBMC-associated viral RNA
in vivo peaked 48 h after JQ1 and prostratin injection, we isolated
circulating resting CD4+ T cells from PBMCs in each animal at this
time point, and evaluated the viral RNA and DNA by real-time PCR.
In agreement with the ex vivo results, HIV-1 replication was
elevated in resting CD4+ T cells after the two doses of JQ1 and pros-
tratin. Compared with the baseline, resting CD4+ T cell-associated
RNA (rc-RNA) was greatly upregulated by 46-fold (range 13.1–76.2)
and 32-fold (range 18.8–57.1) after the first and second dose,
respectively (Fig. 5a). However, neither treatment produced a sig-
nificant change in resting CD4+ T cell-associated DNA (rc-DNA)
(P > 0.05) (Fig. 5b).
3.6. Viral reservoir harbored some lymphoid tissues can be reactivated
in vivo
The lymphoid organs are primary sites of HIV-1 replication and
contain more than 98% of CD4+ T cells in humans [38]. To evaluate
the extent of HIV-1 latency in lymphoid tissue and the degree of
LRA activation, at 150 wpi, or 9 weeks after the second dose, ani-
mal 05001 was injected with a third dose of JQ1 and prostratin.
The animal was sacrificed 48 h after LRA treatment and the PBMCs,
ileum, colon, inguinal lymph nodes (ILN), mesenteric lymph nodes
(MLN), and spleen were isolated at necropsy. In resting CD4+ T cells
isolated from the PBMC and ILN, LRA stimulation produced no sig-
nificant change in viral DNA levels, which was consistent with the
results for doses 1 and 2. The viral DNA levels in the colon and MLN
were higher than in other organs, suggesting that these organs
might be viral sanctuaries in vivo (Fig. 5c). These results were sim-
ilar to data obtained from simian immunodeficiency virus (SIV)-
infected pig-tailed macaques after HAART [39]. On the other hand,
the levels of resting CD4+ T-cell-associated viral RNA from PBMC
and ILN were up-regulated by 29- and 17-fold, respectively
(Fig. 5d). Because we did not have baseline values for the other
organs, we could not determine whether and to what extent viral
reservoirs at other sites were activated.
To further confirm that latent viruses were activated by JQ1 and
prostratin, ILN and colon tissues from animal 05001 weresubjected to pathological analysis. HE staining showed that these
organs had no obvious pathological changes, and there were no
significant microbial translocations as indicated by LPS staining
(Supplemental Fig. 8). However, HIV-1 p24 staining revealed high
expression levels in these organs after stimulation, which might
be due to viral reservoir reactivation (Fig. 6).4. Discussion and conclusion
The discovery in 1992 that pig-tailed macaques (M. nemestrina)
were susceptible to infection by HIV-1 [1] increased the enthusi-
asm for developing a NHP model to study pathogenic HIV-1 infec-
tion. Thus, many studies during the 1990s concentrated on the
following four aspects: (1) optimizing inoculation routes and doses
[2,3,6,7], (2) selection of various viral strains [3,4,7], (3) in vivo pas-
sage of HIV-1 in pig-tailed macaques [8,9], and (4) introduction of
minimally modified HIV-1 strains to evade innate immune sensing
[13–16]. Here, we showed that HIV-1 could replicate at a low level
and form a long-term viral reservior in northern pig-tailed maca-
ques (M. leonina, NPM), which extends earlier findings and broad-
ens the understanding of HIV-1 latency in non-pathogenic animal
models [40].
Early reports indicated that HIV-1 could only form a weak pri-
mary infection in M. nemestrima; in our studies, we initially
attempted to establish an optimizational model of HIV-1-infected
M. leonina, and to our disappointment, although the initial infec-
tion became viremic and seroconverted, HIV-1 replication dimin-
ished markedly within 12 weeks after infection and did not
rebound thereafter, consistent with that of M. nemestrima. How-
ever, the continued presence of HIV-1- specific antibodies, the
detectable HIV-1 genes and successful re-isolation of HIV-1 parti-
cles after approximately 3 years of monitoring documented herein
were much more progresses than previously observed using HIV-1
in M. nemestrima, which might result from distinct genetic back-
grounds between M. leonina and M. nemestrima, or different meth-
ods for genes amplification and virus isolation, the reason needed
further examinations.
There were several clues that supported viral persistent replica-
tion in NPMs. (1) A mild viral replication at early stages of infec-
tion, a controlling viremia but persistent HIV-1 antibodies were
found during 3 years of infection. (2) Persistent cell-associated
HIV-1 DNA and RNA were detected in this model. (3) The viral
reservoir (cell-associated DNA) in NPMs was stable through longi-
tudinal post-infection even at the strict control of immunologic
mechanisms.
The precise definition of the nature of HIV-1 viral reservoir is
still debated, but it hallmarks as the presence of a small popula-
tion of resting CD4+ T cells harboring little, or non-expressing,
integrated HIV proviruses which can be induced to produce
Fig. 5. HIV-1 replication in resting CD4+ T cells up-regulated by in vivo administration of JQ1 and prostratin. Two dose of JQ1 and prostratin was given to 4 HIV-1 infected
animals at 138 and 141 wpi, at 48 h after treatment, resting CD4+ T cells were isolated from peripheral blood of infected NPMs. (a) Cell-associated viral DNA (rc-DNA) and (b)
Cell-associated viral RNA (rc-RNA) were analyzed by quantitative PCR. Nine weeks after the second stimulation, a third treatment of JQ1 and prostratin was given to animal
05001 on 150 wpi. The animal was sacrificed 48 h after treatment, and the resting CD4+ T cells were isolated from several lymphoid tissues. (c) The rc-DNA and (d) rc-RNA in
purified CD4+ T cells was analyzed by quantitative PCR. The data were presented as mean ± SEM. P values were determined by paired t test.
Fig. 6. Immunohistochemistry of HIV-1 replication in lymphoid tissues. Animal 05001 was injected with JQ1 and prostratin and sacrificed 48 h later. Immunohistochemistry
was performed with anti-p24 antibody on paraffin sections of lymph nodes (ILN), spleen, and colon. Scale bars, 50 mm.replicationcompetent viruses upon stimulation [41]. Several lines
of evidence from our study support that, similar to those found in
humans, HIV-1-infected NPM likely have HIV-1 reservoirs: (1)
resting CD4+ T cells in both peripheral blood and lymphoid tis-
sues carried a small number of HIV proviruses (ranging from 2
to 3 log10 per million resting CD4+ T cells), and the provirusesin PBMCs could be partly recovered even at late time points of
infection; (2) HIV proviruses in resting CD4+ T cells could be reac-
tivated in vitro and in vivo in response to strong stimulatory sig-
nals provided by LRAs; and (3) plasma viremia transiently
rebounded, and tissue-distributed viruses could be reactivated
by LRA treatment.
In this study, HIV-1 transcription and replication in NPMs were
greatly reactivated by LRAs JQ1 and prostratin. The small molecule
JQ1, with its high specificity for BRD4, can interfere with BRD4
binding to transcription factor pTEFb, then pTEFb was released
from HIV-1 promoter, and interacts with Tat to promote HIV-1
transcription elongation [30,31]. Prostratin, an activator of protein
kinase C, can promote the translocation of the transcription factor
NF-jB into cell nucleus, where it can bind to the HIV LTR and ini-
tiate HIV-1 transcription [42]. Although JQ1 and Prostratin have
shown potential ability to reverse HIV-1 latency in vitro, concerns
regarding toxicities have impeded their clinical studies. JQ1 has
demonstrated good tolerability of twice-daily administration at
intraperitoneal dose of 100 mg/kg in mice when it was applied in
cancer researches [43]. However, no data were presented in other
animals, such as macaques. As for Prostratin, studies were con-
ducted in CD2F1 mice using both the intraperitoneal route at a
dose of 1.9 mg/kg and the intravenous route at a dose of
0.76 mg/kg, no obvious toxicities were observed. The maximum
tolerated dose (MTD) in Fisher rats ranged from 0.2 to 0.4 mg/kg.
In rhesus macaques, a single intravenous dose of either 0.1 or
0.4 mg/kg was well tolerated. At the 0.6 mg/kg dose, the monkey
particular exhibited severe hepatotoxicity with 25- to 50-fold
increases in level of ALT and AST over baseline measurements.
The monkey injected with 0.8 mg/kg prostratin died of a respira-
tory failure [44]. In this study, to reactivate the latent HIV-1
in vivo, we selected a dose of JQ1 (100 mg/kg) and prostratin
(80 mg/kg) combination by intravenous injection to each NPM. All
macaques tolerated well and showed no obvious clinical side
effects. This study could provide some valuable information for
the preclinical toxicity evaluation of JQ1 and prostratin.
To date, there is little evidence showing that LRAs can upregu-
late in vivo viral RNA levels in resting CD4+ T cells. Vorinostat and
romidepsin, belonging to histone deacetylase inhibitors, were the
only two LRAs that can produce marginal increases in viral RNA
in clinical trials [45,46], whereas other LRAs showed inconsistent
or negative results [47–49]. Thus, more robust LRAs either alone
or in combination should be tested in the future [37,50], and pre-
clinical animal models are urgently needed for further evaluations.
The HIV-1-infected NPMs in this study represent an animal model
of the rebound in HIV-1 replication both ex vivo and in vivo after
stimulation with a combination of JQ1 and prostratin, which reca-
pitulated the main features of HIV-1 latency reversing ex vivo
model in humans [34,37]. Therefore, these in vivo results could
give some clues for clinical study of LRAs.
Although long-term HIV infection in NPMs indeed showed a
viral reservoir that recapitulated some features of HIV-1 latency
in humans and was responsive to LRA stimulation, expanding this
model for use as a testing platform for HIV-1 latency-reversing
strategies should be carefully examined in future studies. The tem-
porary viral replication and rebound implied a strong repression of
immunological control in NPMs, suggesting that the HIV-1 infec-
tion in these animals was partly permissive. It may be due to the
antagonism of host antiretroviral factors such as APOBEC3 and
tetherin, or the restriction of CD8+ cells and major histocompatibil-
ity complexes to HIV-1 [16]. Thus, the HIV-1 viral reservoir formed
in NPMs is likely to be mediated by different mechanisms than
those in elite controllers or patients under HAART treatment. Fur-
ther improvements of this model as well as a detailed understand-
ing of viral latency mechanisms could be achieved by systemic
comparison of LRA efficiencies in NPMs and in human patients,
and through inoculation with stHIV-1 recombinants or SIV that
have more robust replication capacity in NPMs [51].
In summary, HIV-1 can infect NPMs and a long time viral reser-
voir was formed in vivo. LRAs JQ1 and prostratin could reactivate
this viral reservoir, indicating that NPMs are a potential model to
be developed for HIV-1 reservoirs research.Conflict of interest
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